Journal
CURRENT ONCOLOGY REPORTS
Volume 21, Issue 2, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-019-0763-9
Keywords
Signaling; Cancer; Canonical; Non-canonical; Clinical trial; FDA approved; Wnt; -catenin; Wnt; Ca2+; Wnt; PCP; Wnt inhibitor; -Catenin
Categories
Funding
- Western University of Health Sciences
Ask authors/readers for more resources
Purpose of ReviewReview current understanding of both canonical and non-canonical Wnt signaling in cancer and provide updated knowledge in current clinical trials of Wnt signaling drugs.Recent FindingsImportant roles of both canonical and non-canonical Wnt signaling in cancer have been increasingly recognized. Recent clinical trials of several Wnt-signaling drugs have showed promising outcomes. In addition, some drugs that were originally approved for the treatment of other diseases have been recently found to block Wnt signaling, highlighting their potential to treat Wnt-dependent cancer.SummaryDysfunction of Wnt signaling is implicated in cancer, and targeting Wnt signaling represents a useful approach to treat cancer. Current clinical trials of Wnt signaling drugs have showed promising outcomes, and repurposing the previously approved drugs for other diseases to treat Wnt-dependent cancer requires further studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available